About this trial
This phase IV trial compares methadone versus hydromorphone given in the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord (intrathecal) for postoperative pain relief in patients with gynecologic cancer undergo surgery. Methadone binds to opioid receptors in the central nervous system and is a long-acting opioid pain medication. Intrathecal hydromorphone works by changing the way the brain and nervous system respond to pain and is similar to an epidural. This trial may help researchers determine if methadone works as well as intrathecal hydromorphone for pain relief after surgery in patients with gynecologic cancer.
Eligibility criteria
Qualifiers
Undergoing surgery with a laparotomy for gynecologic malignancy
Planned inpatient admission greater than 24 hours
Disqualifiers
Chronic pain requiring greater than 20 morphine milligram equivalents of opioid medications as an outpatient
Prolonged corrected QT interval (QTc) > 500ms
Chronic kidney disease with estimated glomerular filtration rate (eGFR) < 30 milliliters per minute (mL/min)
Documented cirrhosis
Trial design
Treatments tested in this trial
- Hydromorphone
- Methadone
- Questionnaire Administration